{"organizations": [], "uuid": "37df8f057a3405f291b34f0061c978fa71fd1ef1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-approves-xgeva-for-the-prevent/brief-fda-approves-xgeva-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-idUSASB0BZWZ", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T16:07:00.000+02:00", "replies_count": 0, "uuid": "37df8f057a3405f291b34f0061c978fa71fd1ef1"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-approves-xgeva-for-the-prevent/brief-fda-approves-xgeva-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-idUSASB0BZWZ", "ord_in_thread": 0, "title": "BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 5, 2018 / 2:08 PM / Updated 8 minutes ago BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Reuters Staff \nJan 5 (Reuters) - Amgen Inc: \n* FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA \n* AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 ‘482 STUDY WHICH ENROLLED 1,718 PATIENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T16:07:00.000+02:00", "crawled": "2018-01-05T16:22:00.018+02:00", "highlightTitle": ""}